Evaluation and treatment of malignant ascites secondary to gastric cancer - Wikidata - wikimedia - TriplyDB

Evaluation and treatment of malignant ascites secondary to gastric cancer

Evaluation and treatment of malignant ascites secondary to gastric cancer

http://www.wikidata.org/entity/Q26780301

about

Difficulties in differentiating the nature of ascites based on ultrasound imaging.Secreted frizzled-related protein 1 overexpression in gastric cancer: Relationship with radiological findings of dual-energy spectral CT and PET-CT.Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants.Quantification of ascites based on abdomino-pelvic computed tomography scans for predicting the in-hospital mortality of liver cirrhosis.Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT.

P2860

Q38601375-521352A9-550E-4B29-BD17-E584D23D03EE Q38717524-B04453A2-EFBE-40E7-BFDA-1264AB6CFF18 Q39703529-1B647B86-7463-46EB-B670-D77F1D7FC719 Q47147228-96A37344-223B-4260-AB91-E1614643462E Q50009971-7895A192-A373-493C-826A-AE6925E96175

P2860

Evaluation and treatment of malignant ascites secondary to gastric cancer

http://www.wikidata.org/entity/Q26780301

description

2015 nî lūn-bûn

@nan

2015 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Evaluation and treatment of malignant ascites secondary to gastric cancer

@ast

Evaluation and treatment of malignant ascites secondary to gastric cancer

@en

Evaluation and treatment of malignant ascites secondary to gastric cancer

@nl

type

label

Evaluation and treatment of malignant ascites secondary to gastric cancer

@ast

Evaluation and treatment of malignant ascites secondary to gastric cancer

@en

Evaluation and treatment of malignant ascites secondary to gastric cancer

@nl

prefLabel

Evaluation and treatment of malignant ascites secondary to gastric cancer

@ast

Evaluation and treatment of malignant ascites secondary to gastric cancer

@en

Evaluation and treatment of malignant ascites secondary to gastric cancer

@nl

P1433

Q26780301-4C73F789-A035-4006-A2A6-03A9C76C628A

P1476

Q26780301-E44CA161-2BE7-4513-AC1D-4F6B237749F1

P2093

Q26780301-04B08AB3-5513-428B-8114-3234DFEEF1E3

Q26780301-731CB896-B1AD-4BB1-8390-01E6DA9C99FF

Q26780301-A49F20C4-0F8D-4E71-A87C-BC82416F5FC0

P2860

Q26780301-113ABDF4-B3F0-4CCE-9CB0-AED25E62FCDF

Q26780301-122F071D-A6C2-44B5-9A1C-A844A8CD441A

Q26780301-13B4E80D-39C0-42AA-8C0C-C8CE32E40FBA

Q26780301-1474C6E1-CD7D-4C36-8192-A26EECA2CE95

Q26780301-158198D8-AD99-413B-B1EA-E180D27FF1B7

Q26780301-17703BB2-1634-441B-8F5F-9881B436BD89

Q26780301-1EDB9AF3-9535-4F5C-9CDC-B8248228003F

Q26780301-28370B74-B1D9-4938-A449-914EFBFC27C2

Q26780301-29886706-CA38-4B36-8230-A17C71729861

Q26780301-2A27114F-B58A-4AA8-A2A8-1FB6F8850BE5

P304

Q26780301-F1B1C0BE-36E0-4514-953B-6F27B9C56F5E

P31

Q26780301-6D0D77A0-4119-45EB-AD2D-AB5432A82148

P356

Q26780301-E1B625B9-01CD-43E8-BFBD-C0D170208663

P407

Q26780301-5FD4B025-33AC-4EF8-B1AF-D5276D3825FE

P433

Q26780301-E171D471-D47F-497C-B26C-7DA9F124268A

P478

Q26780301-749A49DC-4CA1-49B8-9E7A-CC358B58A7C3

P577

Q26780301-3055DC1E-3420-42E9-BE97-D355FABE492C

P5875

Q26780301-0F91FD12-7834-49D1-98BB-43A0204BE7F8

P698

Q26780301-37BB17ED-6F2A-479A-A2AB-55D68A082DF2

P932

Q26780301-1B6D4CD1-E102-4F07-9755-367386AF6BB8

P356

WJG.V21.I39.10936

P1433

World Journal of Gastroenterology

P1476

Evaluation and treatment of malignant ascites secondary to gastric cancer

@en

P2093

Hiromichi Maeda

http://www.w3.org/2001/XMLSchema#string

Junichi Sakamoto

http://www.w3.org/2001/XMLSchema#string

Michiya Kobayashi

http://www.w3.org/2001/XMLSchema#string

P2860

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

The use of a pocket-sized ultrasound device improves physical examination: results of an in- and outpatient cohort study.

Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.

Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites

Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer.

Malignant ascites: pathophysiology and treatment.

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Predicting the amount of intraperitoneal fluid accumulation by computed tomography and its clinical use in patients with perforated peptic ulcer.

Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials.

P304

10936-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V21.I39.10936

http://www.w3.org/2001/XMLSchema#string

P407

P433

39

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283286606

http://www.w3.org/2001/XMLSchema#string

P698

26494952

http://www.w3.org/2001/XMLSchema#string

P932

4607895

http://www.w3.org/2001/XMLSchema#string